Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Depreciation & Amortization (CF) (2020 - 2025)

Historic Depreciation & Amortization (CF) for Bioventus (BVS) over the last 6 years, with Q3 2025 value amounting to $11.4 million.

  • Bioventus' Depreciation & Amortization (CF) fell 710.39% to $11.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.7 million, marking a year-over-year decrease of 381.54%. This contributed to the annual value of $49.6 million for FY2024, which is 1361.46% down from last year.
  • Per Bioventus' latest filing, its Depreciation & Amortization (CF) stood at $11.4 million for Q3 2025, which was down 710.39% from $12.0 million recorded in Q2 2025.
  • In the past 5 years, Bioventus' Depreciation & Amortization (CF) registered a high of $16.9 million during Q4 2022, and its lowest value of $7.2 million during Q2 2021.
  • For the 5-year period, Bioventus' Depreciation & Amortization (CF) averaged around $12.2 million, with its median value being $12.4 million (2022).
  • In the last 5 years, Bioventus' Depreciation & Amortization (CF) skyrocketed by 7370.55% in 2022 and then plummeted by 2845.87% in 2024.
  • Quarter analysis of 5 years shows Bioventus' Depreciation & Amortization (CF) stood at $11.7 million in 2021, then surged by 44.93% to $16.9 million in 2022, then fell by 26.43% to $12.5 million in 2023, then fell by 0.48% to $12.4 million in 2024, then dropped by 8.08% to $11.4 million in 2025.
  • Its last three reported values are $11.4 million in Q3 2025, $12.0 million for Q2 2025, and $11.9 million during Q1 2025.